Vaccine Market Growth Report

1
Vaccine Market Size, Share Trends Analysis
Report and Segment Forecast, 2024 Grand View
Research, Inc
The global Vaccine Market was valued at over USD
32.5 billion in 2015 and is expected to grow at
a CAGR of 10.3 over the forecast period.
The global Vaccine Market valuation is expected
to exceed USD 77.5 billion by 2024, according to
a new report by Grand View Research, Inc.
Development of various molecules to cater to the
growing demand for vaccines can drive market
demand. Majority of the key players are focused
on vaccine development to gain an edge over
competitors. For instance, Pfizer, Inc., is
developing vaccines for Clostridium difficile,
Staphylococcus aureus, and Meningococcal
B. Furthermore, the broad coalition of
governments, worldwide, working to promote the
awareness of vaccination benefits through
immunization programs with the objective of
containing the propagation of communicable
diseases that are associated with high morbidity
and mortality is expected to stimulate the market
growth. For instance, the Immunize Australia
Program sponsors the immunization of
individuals, which acts as a preventative action
in preventing disease occurrence and checks
rampant disease transmission thus protecting
millions of Australians from severe diseases.
Another program that has been involved in
achieving extensive immunization coverage on the
Indian continent is the National Immunization
Program, a government program that has focused
on taking strong preventive measures to offset
vaccine-preventable diseases, particularly in
children. To request a sample copy or view
summary of this report, click the link
below http//www.grandviewresearch.com/industry-a
nalysis/vaccine-market Further key findings from
the study suggest
2

• The inactivated vaccine type segment was
  estimated to have over 14.5 market share in 2015
  owing to the related advantages including easy
  storage and transport due to the highly stable
  nature of these vaccines. In December 2015,
  Sanofi Pasteur, Inc. launched a new trivalent,
  inactivated polio vaccine in India.
• The DNA vaccine segment is presumed to be the
  fastest growing type over the forecast period
  owing to the ease of production compared to the
  cell-based vaccines and the promising, targeted
  immunization outcomes coupled with the continual
  developments in the biotechnology area. Other
  advantages associated are ease of production,
  long lasting immunogenicity, and no risk of
  reversion.
• The cancer application segment is expected to
  witness the fastest growth with a CAGR of over
  11.8 in the vaccinations market majorly
  attributable to the need for immunization against
  cancer coupled with the increasing prevalence of
  various types of cancer, such as cervical and
  colorectal cancers.
• North America dominated the market in terms of
  revenue with over USD 12 billion in 2015, due
  mainly to the presence of extensive research and
  development activities and the existence of key
  participants of the industry in this region
• Asia Pacific is identified to witness a lucrative
  growth with a CAGR of around 10.7 during the
  forecast period due to the growing population
  base and the increasing economic growth of
  countries, such as China, Japan, and India.
  Moreover, the availability of skilled labors at a
  lower cost and the low manufacturing operations
  cost provide a platform for clinical trial
  outsourcing of the vaccinations under
  development to expedite commercialization.
• Leading players in this industry, among others
  are, Merck Co., Inc., Emergent BioSolutions,
  Inc., Johnson and Johnson, Sanofi Pasteur, Inc.,
  Pfizer, Inc., Novartis AG, CSL Ltd., and
  GlaxoSmithKline Plc. Other prominent players
  include Abbott Laboratories, Inc., AstraZeneca
  plc, Janssen Pharmaceuticals, Inc., Takeda
  Pharmaceuticals Company Ltd., and Valeant
  Pharmaceuticals International, Inc.
• In April 2016, VBI vaccines, Inc. entered into a
  collaborative agreement with Sanofi Pasteur, Inc.
  to employ its Lipid Particle Vaccine
  formulation technology to better the stability of
  the Sanofi vaccines.
• Grand View Research has segmented the global
  vaccines market on the basis of type,
  application, and region
• Global Vaccines Market By Type (Revenue, USD
  Million, 2013 - 2024)
• Inactivated vaccines

3

• Toxoid vaccines
• Others
• Global Vaccines Market By Application (Revenue,
  USD Million, 2013 - 2024)
• Infectious diseases
• Cancer
• Autism
• Allergy
• Others
• Vaccines Market By Region (Revenue, USD Million,
  2013 - 2024)
• North America

4

• Table of Content of Vaccine Market
• Chapter 1 Methodology and Scope
• Research Methodology
• Research Scope Assumptions
• Company Market Share Analysis Methodology
• Chapter 2 Executive Summary Chapter 3 Market
  Snapshot
• Chapter 4 Market Variables, Trends Scope
• Market segmentation scope
• Market size and growth prospects
• Market Driver Analysis
• Rise in importance of immunization across the
  globe
• High predominance of chronic diseases
• Technology advancements in the types of vaccines
• Other drivers
• Market Restraint Analysis
• Cost of immunization
• Lack of healthcare infrastructure
• Penetration growth prospect mapping

5

• 5.5.1 Toxoid Vaccine Market, 2013 - 2024 (USD
  Million)
• Conjugate vaccines
• Conjugate Vaccine Market, 2013 - 2024 (USD
  Million)
• DNA vaccines
• DNA Vaccine Market, 2013 - 2024 (USD Million)
• Others
• Other Vaccine Market, 2013 - 2024 (USD Million)
• Chapter 6 Market Categorization 2 Vaccine
  Application Estimates Trend Analysis
• Vaccine Market Application movement analysis
• Infectious Diseases
• Infectious Diseases market, 2013 - 2024 (USD
  Million)
• Cancer
• Cancer market, 2013 - 2024 (USD Million)
• Allergy
• Allergy market, 2013 - 2024 (USD Million)
• Others
• Other applications market, 2013 - 2024 (USD
  Million)
• Chapter 7 Market Categorization 3 Regional
  Estimates Trend Analysis, by Type Application
• Vaccine Market share by region, 2015 2024

6

• 7.6.1 South Africa
• Chapter 8 Competitive Landscape
• Strategy framework
• Market participation categorization
• Company Profiles
• Merck Co. Inc
• Company Overview
• Financial Performance
• Product Benchmarking
• Strategic Initiatives
• GlaxoSmithKline plc (GSK)
• Company Overview
• Financial Performance
• Product Benchmarking
• Strategic Initiatives
• SANOFI S.A
• Company Overview
• Financial Performance
• Product Benchmarking

7

• Company Overview
• Financial Performance
• Product Benchmarking
• Strategic Initiatives
• Astellas Pharma Inc.
• Company Overview
• Financial Performance
• Product Benchmarking
• Strategic Initiatives
• Emergent BioSolutions
• Company Overview
• Financial Performance
• Product Benchmarking
• Strategic Initiatives
• AstraZeneca
• Company Overview
• Financial Performance
• Product Benchmarking
• Strategic Initiatives

8
About Us Grand View Research, Inc. is a U.S.
based market research and consulting company,
registered in the State of California and
headquartered in San Francisco. The company
provides syndicated research reports, customized
research reports, and consulting services. To
help clients make informed business decisions,
the company offers market intelligence studies
ensuring relevant and fact-based research across
a range of industries including technology,
chemicals, materials, healthcare and
energy. Contact Sherry James Corporate Sales
Specialist, USA Grand View Research, Inc Phone
1-415- 349-0058 Toll Free 1-888- 202-9519 Email
sales_at_grandviewresearch.com For More Information
https//www.grandviewresearch.com Blog
https//healthcareforecastreport.blogspot.com/